Cargando…
蛋白降解靶向嵌合体在非小细胞肺癌治疗中的研究进展
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the ef...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346157/ https://www.ncbi.nlm.nih.gov/pubmed/35899444 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.19 |